Orphazyme A/S (OZYMF)
USD 90.0
(0.0%)
USD 90.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.07 Million DKK | -68.02% |
| 2022 | 15.85 Million USD | -36.71% |
| 2021 | 25.04 Million DKK | -24.55% |
| 2020 | 33.19 Million DKK | 72.95% |
| 2019 | 19.19 Million DKK | -63.85% |
| 2018 | 53.1 Million DKK | 12.7% |
| 2017 | 47.11 Million DKK | 226.46% |
| 2016 | 14.43 Million DKK | 33.52% |
| 2015 | 10.8 Million DKK | 81.15% |
| 2014 | 5.96 Million DKK | 48.54% |
| 2013 | 4.01 Million DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 252.35 Thousand USD | 0.0% |
| 2023 Q1 | 7.29 Million DKK | -55.65% |
| 2023 Q2 | 7.29 Million USD | 0.0% |
| 2023 Q3 | 5.07 Million DKK | -30.53% |
| 2023 Q4 | 5.07 Million USD | 0.0% |
| 2023 FY | 5.07 Million DKK | -68.02% |
| 2022 Q2 | 2.16 Million DKK | -85.95% |
| 2022 Q4 | 16.45 Million USD | 4.46% |
| 2022 FY | 15.85 Million USD | -36.71% |
| 2022 Q1 | 15.38 Million DKK | -90.61% |
| 2022 Q3 | 15.75 Million DKK | 628.82% |
| 2021 Q1 | 261.26 Million DKK | 29.36% |
| 2021 Q2 | 261.27 Million DKK | 0.0% |
| 2021 Q3 | 163.89 Million DKK | -37.27% |
| 2021 Q4 | 163.89 Million DKK | 0.0% |
| 2021 FY | 25.04 Million DKK | -24.55% |
| 2020 Q1 | 170.22 Million DKK | 33.21% |
| 2020 FY | 33.19 Million DKK | 72.95% |
| 2020 Q4 | 201.96 Million DKK | 0.0% |
| 2020 Q2 | 170.22 Million DKK | 0.0% |
| 2020 Q3 | 201.96 Million DKK | 18.65% |
| 2019 Q3 | 127.78 Million DKK | 136.21% |
| 2019 Q4 | 127.78 Million DKK | 0.0% |
| 2019 Q1 | 54.09 Million DKK | 1.88% |
| 2019 Q2 | 54.09 Million DKK | 0.0% |
| 2019 FY | 19.19 Million DKK | -63.85% |
| 2018 Q4 | 53.1 Million DKK | 0.2% |
| 2018 FY | 53.1 Million DKK | 12.7% |
| 2018 Q2 | 35.33 Million DKK | 0.0% |
| 2018 Q1 | 35.33 Million DKK | -25.01% |
| 2018 Q3 | 52.99 Million DKK | 49.99% |
| 2017 Q3 | 47.11 Million DKK | 92.98% |
| 2017 FY | 47.11 Million DKK | 226.46% |
| 2017 Q2 | 24.41 Million DKK | 0.0% |
| 2017 Q1 | 24.41 Million DKK | 69.17% |
| 2017 Q4 | 47.11 Million DKK | 0.0% |
| 2016 Q3 | 14.43 Million DKK | 0.0% |
| 2016 Q4 | 14.43 Million DKK | 0.0% |
| 2016 Q1 | - DKK | 0.0% |
| 2016 FY | 14.43 Million DKK | 33.52% |
| 2015 FY | 10.8 Million DKK | 81.15% |
| 2014 FY | 5.96 Million DKK | 48.54% |
| 2013 FY | 4.01 Million DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -56.024% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 90.489% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1102.653% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.868% |
| Intellipharmaceutics International Inc. | 12 Million USD | 57.781% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 93.004% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 91.409% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -31.64% |
| Marizyme, Inc. | 26.67 Million USD | 80.994% |
| Genus plc | 485 Million USD | 98.955% |
| Pharming Group N.V. | 244.07 Million USD | 97.923% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -152.222% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -101.484% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -33.421% |
| ContraFect Corporation | 32.53 Million USD | 84.415% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -32.457% |
| IMV Inc. | 37.93 Million USD | 86.634% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 56.954% |
| ONE Bio Corp. | 27.49 Million USD | 81.561% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.451% |
| Mesoblast Limited | 188.44 Million USD | 97.31% |
| MultiCell Technologies, Inc. | 1617.67 USD | -313313.737% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.887% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.618% |
| Neon Bloom, Inc. | 1.22 Million USD | -313.468% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 1.478% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 47.088% |
| Biomind Labs Inc. | 1.49 Million USD | -238.313% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 43.93% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 72.451% |
| Skye Bioscience, Inc. | 14.07 Million USD | 63.972% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -253.591% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 13.224% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3468.035% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -155.892% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 46.439% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2420.933% |
| Accustem Sciences Inc. | 1.07 Million USD | -369.775% |
| EV Biologics, Inc. | 2.11 Million USD | -139.708% |
| Q BioMed Inc. | 8.13 Million USD | 37.661% |
| GB Sciences, Inc. | 5.41 Million USD | 6.415% |
| Alpha Cognition Inc. | 7.16 Million USD | 29.237% |
| CSL Limited | 18.62 Billion USD | 99.973% |
| Agentix Corp. | 2.51 Million USD | -101.947% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.73% |
| Enzolytics Inc. | 365.26 Million USD | 98.612% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 92.477% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -504.484% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 11.762% |
| argenx SE | 444.95 Million USD | 98.861% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.233% |
| HST Global, Inc. | 593.59 Thousand USD | -754.121% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -195.799% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -302.639% |
| Halberd Corporation | 728.71 Thousand USD | -595.741% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 79.512% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -38.329% |
| Zenith Capital Corp. | 27.56 Thousand USD | -18290.221% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 57.406% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -35.768% |
| AVAX Technologies, Inc. | 3.99 Million USD | -26.949% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -644.675% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -86.972% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2024.414% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 35.502% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7475.192% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.913% |
| Kadimastem Ltd | 3.5 Million USD | -44.656% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 68.123% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -991.029% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -18381.391% |
| LadRx Corporation | 2.2 Million USD | -130.399% |
| Cell Source, Inc. | 15.8 Million USD | 67.925% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -11243.297% |
| Regen BioPharma, Inc. | 5.45 Million USD | 7.102% |
| Regen BioPharma, Inc. | 5.45 Million USD | 7.102% |
| Affymax, Inc. | 8.87 Million USD | 42.847% |
| Mobile Lads Corp. | 1.31 Million USD | -285.993% |
| Itoco Inc. | 1.65 Million USD | -206.687% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -147.128% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 16.184% |
| International Stem Cell Corporation | 5.27 Million USD | 3.923% |
| CytoDyn Inc. | 127.89 Million USD | 96.036% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12029.477% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -223.677% |
| Qrons Inc. | 1.48 Million USD | -240.563% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 54.098% |
| SYBLEU INC | 681.41 Thousand USD | -644.042% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -526.859% |
| Rebus Holdings, Inc. | 5.24 Million USD | 3.281% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 16.911% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -710.151% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -9.809% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 87.633% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 77.229% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -150.323% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 7.448% |
| Neutra Corp. | 973.52 Thousand USD | -420.786% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 82.526% |
| PureTech Health plc | 125.58 Million USD | 95.963% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -34.944% |
| IXICO plc | 1.9 Million USD | -166.801% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 75.303% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.093% |
| CSL Limited | 18.62 Billion USD | 99.973% |
| Cellectis S.A. | 249.36 Million USD | 97.967% |